Abstract
Recanalization therapy remains the most effective way for treatment of evolving myocardial infarction and thereby salvaging jeopardized tissue. However, the efficacy of reperfusion in limiting infarction and improving recovery of contractile function depends on the amount of irreversible damage occurring prior to initiating reperfusion and is related to failure of energy production to meet the basal needs of the injured myocardium. In recent years, a variety of metabolic therapies that enhance myocardial metabolism and attenuate changes in sodium and calcium homeostasis during ischemia have been proposed. They focus on (a) increasing myocardial glucose metabolism during ischemia or (b) inhibiting fatty acid metabolism to increase glucose use, and (c) inhibiting sodium and calcium influx pathways that deplete high energy phosphates. Recent studies from our laboratory showed that inhibition of aldose reductase, a key regulatory enzyme in the substrate flux via polyol pathway, reduces ischemic injury and improves functional and metabolic recovery after ischemia-reperfusion in hearts. These and subsequent studies have generated considerable interest in the use of aldose reductase inhibitors as potential therapeutic adjuncts in treating evolving myocardial infarction in patients. This review will discuss the mechanisms by which aldose reductase inhibitors protect ischemic myocardium and provide rationale for their use as cardioprotective drugs.
Keywords: aldose reductase, cardioprotective interventions, recanalization therapy, calcium homeostasis, ischemia, myocardial glucose metabolism, ischemic myocardium, cardioprotective drugs
Current Drug Targets
Title: Aldose Reductase: A Novel Target for Cardioprotective Interventions
Volume: 4 Issue: 8
Author(s): Ravichandran Ramasamy
Affiliation:
Keywords: aldose reductase, cardioprotective interventions, recanalization therapy, calcium homeostasis, ischemia, myocardial glucose metabolism, ischemic myocardium, cardioprotective drugs
Abstract: Recanalization therapy remains the most effective way for treatment of evolving myocardial infarction and thereby salvaging jeopardized tissue. However, the efficacy of reperfusion in limiting infarction and improving recovery of contractile function depends on the amount of irreversible damage occurring prior to initiating reperfusion and is related to failure of energy production to meet the basal needs of the injured myocardium. In recent years, a variety of metabolic therapies that enhance myocardial metabolism and attenuate changes in sodium and calcium homeostasis during ischemia have been proposed. They focus on (a) increasing myocardial glucose metabolism during ischemia or (b) inhibiting fatty acid metabolism to increase glucose use, and (c) inhibiting sodium and calcium influx pathways that deplete high energy phosphates. Recent studies from our laboratory showed that inhibition of aldose reductase, a key regulatory enzyme in the substrate flux via polyol pathway, reduces ischemic injury and improves functional and metabolic recovery after ischemia-reperfusion in hearts. These and subsequent studies have generated considerable interest in the use of aldose reductase inhibitors as potential therapeutic adjuncts in treating evolving myocardial infarction in patients. This review will discuss the mechanisms by which aldose reductase inhibitors protect ischemic myocardium and provide rationale for their use as cardioprotective drugs.
Export Options
About this article
Cite this article as:
Ramasamy Ravichandran, Aldose Reductase: A Novel Target for Cardioprotective Interventions, Current Drug Targets 2003; 4 (8) . https://dx.doi.org/10.2174/1389450033490768
DOI https://dx.doi.org/10.2174/1389450033490768 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Skeletal Muscle Derived Stem Cells for Myocardial Repair
Recent Patents on Cardiovascular Drug Discovery A Mini-Review on Cardiovascular and Hematological Complications of COVID-19
Coronaviruses The Role of Transesophageal Echocardiography in the Intraoperative Period
Current Cardiology Reviews Calcium Ions in Inherited Cardiomyopathies
Medicinal Chemistry Oxidative Stress During Myocardial Ischaemia and Heart Failure
Current Pharmaceutical Design Genomics and Pharmacogenomics of Age-related Hearing Loss
Current Pharmacogenomics and Personalized Medicine The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling
Current Pharmaceutical Design Late-Onset Glycogen Storage Disease Type 2
Current Molecular Medicine Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Endoplasmic Reticulum Stress-induced Transcriptional Factor CHOP and Cardiovascular Diseases
Current Hypertension Reviews Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia
Current Neurovascular Research HGF as Angiogenic Factor and Therapeutic Approach
Current Signal Transduction Therapy Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
Current Pharmaceutical Design Withdrawal Notice: COVID-19: Outbreak to Global
Anti-Infective Agents Recent Advance in Isoform-Specific Regulation of Adenylyl Cyclase
Current Enzyme Inhibition Editorial [Hot Topic:The Metabolic Treatment of Coronary Artery Disease and Heart Failure(Executive Editor: Pericle Di Napoli)]
Current Pharmaceutical Design Pathogenetic Pathways of Cardiorenal Syndrome and their Possible Therapeutic Implications
Current Pharmaceutical Design Homocysteine, Cardiovascular Inflammation, and Myocardial Remodeling
Cardiovascular & Hematological Disorders-Drug Targets